FDA Approves Gattex® (teduglutide [rDNA Origin]) for Injection for the Treatment of Adult Short Bowel Syndrome
-- First major long-term treatment advance for adult SBS in nearly 40 years ---- U.S. launch in first quarter of 2013 ---- NPS Pharmaceuticals to host conference call on January 2, 2013 at 5:00 PM ET --
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that the U.S. Food and Drug Administration (FDA) has approved Gattex® (Teduglutide [rDNA origin]) for Injection, for subcutaneous use for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support.
Social Media Tools:
Click asset titles for downloads, embeds and more...
Subscribe via RSS
Journalists who register may create email subscriptions to search results and a cart of assets to download. Click here to login, register or edit profile.
What Our Users
"I like the way the DC is easy to navigate, easy to find stories, easy to find when they were filed so you know if they’re out of date, and easy to see an on-line version of the available video" -- Allan C Lee, Director of News and Current Affairs